samedan logo
 
 
 
spacer
home > ebr > spring 2004 > cns, oncology and hiv clinical trials: current trends and future prospects
PUBLICATIONS
European Biopharmaceutical Review

CNS, Oncology and HIV Clinical Trials: Current Trends and Future Prospects

Canvas opinion around the medical and scientific communities as to the therapeutic areas presenting the greatest challenges for the pharmaceutical industry in the 21st Century, and the chances are that CNS disease (a term covering a broad spectrum of pathologies), oncology and HIV infection will be at the top of many people's lists. Whilst some significant advances have occurred in these therapeutic areas over the last decade, the continuing morbidity and mortality associated with a diagnosis in these areas confirms the need for new therapies.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Phil Collis, VP Scientific Affairs and Professor Gordon McVie, Oncology Advisor at Inveresk

Phil Collis has been Vice President of Scientific Affairs, Global Clinical at Inveresk Research in North Carolina since October 2003. He is principally responsible for international strategic client liaison and consulting on clinical development plans, regulatory strategy and feasibility analysis. Prior to this, he was Director and then Vice President of International Operations for PharmaResearch Corporation in the UK. He has also worked as a Principal Clinical Research Scientist, Senior Clinical Research Scientist and Clinical Research Scientist for Glaxo Wellcome Research and Development. Phil gained his PhD in Molecular Genetics and also studied for his BSc (Hons) in Biochemistry at the University of London. He is an Associate of the Royal College of Science and a Member of the Institute for Clinical Research (ICR), the International AIDS Society, British HIV Association and the Drug Industry Association (DIA).


Professor Gordon McVie MD, FRCP, FRCPS, FRCSE, FMedSci, DSc(Hon) is widely regarded as a leading international authority in the research and treatment of cancer. He is currently Director of Cancer Intelligence, an advisory body to biotechnology and pharmaceutical companies, investors, the media and cancer patients. He is a Visiting Professor at Glasgow University, Scotland; honorary Consultant in Medical Oncology at the Welsh Cancer Institute, Cardiff; Clinical Research Director at the European Institute of Oncology, Milan; and Oncology Advisor to Inveresk. Previously Professor McVie was Chief Executive of the Cancer Research Campaign (CRC). He has authored almost 300 peer-reviewed articles, contributed to over 35 books and is currently European Editor for the US Journal of the National Cancer Institute.

spacer
Phil Collis
spacer
spacer
spacer
Gordon McVie
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Protagen Protein Services (PPS) expands capabilities for aggregate analytics to include dynamic light scattering (DLS)

Protein aggregation is a common challenge in the manufacturing of biological products. As one of the most sensitive techniques for the detection of aggregates, dynamic light scattering (DLS) provides a simple, fast and non-destructive testing method. An innovative technique based on a unique cuvette layout allows for accurate measurements with as little as a single ÁL of solution.
More info >>

White Papers

Detecting Integrity Breaches in a range of Pharmaceutical Blister Package Types using Sepha VisionScan

Sepha Limited

Demonstrating the integrity of pharmaceutical blister packs is critically important, as any defects can affect the shelf life and efficacy of the contents. Compared to bulk packaging, blister packs offer improved product integrity, tamper evidence and reduce the likelihood of misuse. Packs can be composed of either a thermoformed polymer or cold formed aluminium tray, with a number of individual pockets to hold the product. After the tablets or capsules are placed in the pockets, the packs are heat sealed with a paper or foil laminate sheet. These various stages can be completed separately or integrated into a single form, fill and seal process. There is a risk of microbial containment or degradation of the contents if any defects are present in the packaging. Such defects can take the form of rips or pinholes in the tray, or lid materials, faulty seals and channel leaks between pockets.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement